Liao et al. prioritized novel drug targets (XBP1, TTC28 and TRPC6) for meningioma by integrating genome-wide association studies and transcriptomics, with RNA sequencing and molecular docking validating them and revealing expressive characteristics, advancing understanding of meningioma’s molecular landscape. This evidence concerns the gene XBP1 and meningioma.